KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $5.7 billion.

  • Vertex Pharmaceuticals' Total Non-Current Liabilities rose 1171.85% to $5.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.7 billion, marking a year-over-year increase of 1171.85%. This contributed to the annual value of $5.7 billion for FY2025, which is 1171.85% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Total Non-Current Liabilities is $5.7 billion, which was up 1171.85% from $6.3 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $6.3 billion for Q3 2025, and its period low was $2.8 billion during Q2 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Total Non-Current Liabilities value was $4.2 billion (recorded in 2023), while the average stood at $4.2 billion.
  • Within the past 5 years, the most significant YoY rise in Vertex Pharmaceuticals' Total Non-Current Liabilities was 3108.29% (2021), while the steepest drop was 534.88% (2021).
  • Over the past 5 years, Vertex Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $3.0 billion in 2021, then rose by 17.27% to $3.6 billion in 2022, then increased by 20.26% to $4.3 billion in 2023, then grew by 19.59% to $5.1 billion in 2024, then increased by 11.72% to $5.7 billion in 2025.
  • Its Total Non-Current Liabilities stands at $5.7 billion for Q4 2025, versus $6.3 billion for Q3 2025 and $5.7 billion for Q2 2025.